Lido Advisors’s Castle Biosciences CSTL Stock Holding History

Lido Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$246K	Sell	10,031 -5	-0%	-$164	﹤0.01%	1673
2025 Q4	$229K	Hold	10,036	–	–	﹤0.01%	1705
2025 Q3	$229K	Buy	10,036 +5	+0%	+$102	﹤0.01%	1625
2025 Q2	$205K	Hold	10,031	–	–	﹤0.01%	1513
2025 Q1	$201K	Sell	10,031 -493	-5%	-$12.2K	﹤0.01%	1389
2024 Q4	$280K	Hold	10,524	–	–	﹤0.01%	1237
2024 Q3	$300K	Hold	10,524	–	–	﹤0.01%	1168
2024 Q2	$229K	Hold	10,524	–	–	﹤0.01%	1237
2024 Q1	$233K	Hold	10,524	–	–	﹤0.01%	1206
2023 Q4	$227K	Buy	+10,524	New	+$185K	﹤0.01%	1156

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lido Advisors's CSTL Position: Q1 2026 in Review

Lido Advisors reduced its Castle Biosciences (CSTL) stake by 0.05% in Q1 2026, selling an estimated $164 and leaving 10,031 shares worth $246K. The position accounts for ﹤0.01% of the portfolio, ranked #1673.

Lido Advisors first reported a position in CSTL in Q4 2023 and has held it in 10 quarters since. The position peaked at $300K in Q3 2024. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

Lido Advisors held 10,031 shares of Castle Biosciences worth $246K as of Q1 2026.
Lido Advisors sold 5 Castle Biosciences shares in Q1 2026, an estimated $164.
Castle Biosciences made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #1673 holding.
Lido Advisors first reported a position in Castle Biosciences in Q4 2023 and has held it in 10 quarters since.
Lido Advisors's Castle Biosciences position peaked at $300K in Q3 2024.
186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.